Over the past seven years, Celgene has emerged as one of the most active and creative deal-makers in the biopharma industry. The Boston Consulting Group’s Biopharma Partnering Survey and Benchmarking analysis examines BD activity and perceptions across the industry, and

This blog was written by Rosana Kapeller, CSO of Nimbus Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. It is the holiday season and as we gorge on delicious and heavy food, and inevitably resolve to eat less

This blog was written by Ankit Mahadevia, CEO at Spero Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. In my experience, looking to the outside world for new pipeline ideas isn’t just the realm of larger companies.   The

The exciting renaissance in cell and gene therapy over the past five years has yielded some of the most innovative medical advances in the industry’s pipeline today.  There are now multiple stories of patients getting “cured” of rare diseases, responding

This blog was written by Kevin Pojasek, CEO at Quartet and Atlas EIR, as part of the “From the Trenches” feature of LifeSciVC. Therapeutic areas and modalities regularly fall in and out fashion usually when promising scientific approaches run aground in

This blog was written by Michael Gladstone, Principal at Atlas Venture, as part of the “From the Trenches” feature of LifeSciVC. For a great company, an IPO is a financing event. Not an exit. Not the end. This is important to

Imagine you were an investor version of Rip Van Winkle. You went to sleep in October 2012 and woke up today. You’d take a quick look at biotech and think we were in a raging bull market. A few thoughts

Venture capital in biotech has had a great run over the past few years: funding going to private biotech companies is at historic highs, new venture funds are getting raised, and exits have been happening via robust IPO and M&A

This blog was written by Vanessa King, CEO of Luc Therapeutics (f.k.a. Mnemosyne Pharmaceuticals), as part of the “From the Trenches” feature of LifeSciVC. High winds and cold rain certainly make a first impression – and that was even before I’d

Yesterday we were excited to see four Atlas portfolio companies selected to receive “Fierce15” awards from FierceBiotech as part of the 2015 “class”. It’s a wonderful honor for them, and for Atlas, and thought it a great moment to reflect

The relative absence of women from significant leadership roles in the biotech industry has rightfully become a front-and-center topic, in part prompted by a wave of coverage on the subject (here, here, here, here). Liftstream’s recent report, titled “Diversifying the

This blog was written by Rosana Kapeller, CSO of Nimbus Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. A few weeks ago, a member of our board sent an email to a group of biotech CSOs suggesting that